Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168103 · ClinicalTrials.gov registry record · Phase 2
Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT00168103 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 126 participants.
The verdict
NCT00168103, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
HAE is a rare disorder characterized by functional C1 esterase inhibitor deficiency. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of swelling of the larynx. This clinical Phase 2/Phase 3 study was designed to provide clinically relevant data on dosing, efficacy and safety in subjects with HAE.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL C1 Esterase Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00168103
The ClinicalTrials.gov registry entry for NCT00168103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00168103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00168103 about?
NCT00168103 is a clinical study titled "Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks". HAE is a rare disorder characterized by functional C1 esterase inhibitor deficiency. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of swelling of the larynx. This clinical Phase 2/Phase 3 study was designed to provid...
What is the current status of trial NCT00168103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2005-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00168103?
The interventions under investigation include: Placebo (BIOLOGICAL), C1 Esterase Inhibitor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00168103?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.